Близкофокусная рентгенотерапия (Буки-терапия).

В настоящее время близкофокусная рентгенотерапия не рекомендуется для лечения МГ ввиду наличия серьезный отдаленный побочных эффектов.

 

VIII. Организация оказания медицинской помощи

 

IX. Дополнительная информация, влияющая на исход заболевания

МГ не является противопоказанием для плановой иммунизации [37,38].

 

X. Критерии оценки качества медицинской помощи

Приказ Минздрава России от 10.05.2017 N 203н "Об утверждении критериев оценки качества медицинской помощи".

 

XI. Список литературы

 

1. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006; 118 (3): 882–887.

2. Colonna V, Resta L, Napoli A, Bonifazi E Placental hypoxia and neonatal haemangioma: clinical and histological observations. Br J Dermatol. 2009; 162(1):208–9

3. Drolet BA, Frieden IJ Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots? Arch Dermatol. 2010; 146(11):1295–1299

4. Mihm MC Jr, Nelson JS Hypothesis: the metastatic niche theory can elucidate infantile hemangioma development. J Cutan Pathol. 2010; 37:83–87

5. Barnes CM, Christison-Lagay EA, Folkman J The placenta theory and the origin of infantile hemangioma. Lymphat Res Biol. 2007; 5(4):245–255

6. Greenberger S, Bischoff J Pathogenesis of infantile haemangioma. Br J Dermatol. 2013; 169(1):12–19

7. Greenberger S, Yuan S, Walsh LA, Boscolo E, Kang KT, Matthews B, Mulliken JB, Bischoff J Rapamycin suppresses selfrenewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol. 2011; 131(12):2467–2476

8. Mulliken JB, Zetter BR, Folkman J In vitro characteristics of endothelium from hemangiomas and vascular malformations. Surgery. 1982; 92(2):348–353

9. https://www.issva.org

10. Bessis D, Bigorre M, Labreze C. Reticular infantile hemangiomas with minimal or arrested growth associated with lipoatrophy. J Am Acad Dermatol. 2015;72(5):828-833

11. Tollefson M.M., Frieden I.J., et al. Early Growth of Infantile Hemangiomas: What Parents’ Photographs Tell Us. Pediatrics 2012; 130(2); 314-20.

12. Chang L.C., Haggstrom A.N., et al. Growth Characteristics of Infantile Hemangiomas: Implications for Management. Pediatrics 2008; 122(2); 360-367.

13. Mulliken JB, Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol. 2004; 50(6): 875-82.

14. Haggstrom, A.N., Lammer E.J., et al. Patterns of Infantile Hemangiomas: New Clues to Hemangioma Pathogenesis and Embryonic Facial Development. Pediatrics 2006; 117(3), 698–703.

15. Nabatian A.S., Milgraum S.S., Hess C.P., et al. PHACE without face? Infantile hemangiomas of the upper body region with minimal or absent facial hemangiomas and associated structural malformations. Pediatric dermatology. 2011; 28(3): 235-241.

16. Christison-Lagay E.R., Burrows P.E., Alomari A., et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J. Pediatr. Surg. 2007; 42(1): 62-7.

17. Iacobas I., Phung T.L., et al. Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring. J. Pediatr. Surg. 2018; 203: 294-300.

18. Chinnadurai S, Snyder K, Sathe N, et al. Diagnosis and Management of Infantile Hemangioma. Rockville, MD: Agency for Healthcare Research and Quality; 2016,

19. Menapace D, Mitkov M, Towbin R, Hogeling M. The changing face of complicated infantile hemangioma treatment. Pediatr Radiol. 2016;46(11):1494-1506

20. Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2019;143(1): 2018-3475.

21. Rialon KL, Murillo R, Fevurly RD, et al. Risk factors for mortality in patients with multifocal and diffuse hepatic hemangiomas. J Pediatr Surg. 2015;50(5):837-841

22. Mamlouk MD, Hess CP. Arterial spin-labeled perfusion for vascular anomalies in the pediatric head and neck. Clin Imaging. 2016; 40(5):1040-1046

23. Huang S.A., Tu H.M., Harney J.W., et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N. Engl. J Med 2000; 343(3): 185-9.

24. Jockin YM, Friedlander SF. Periocular infantile hemangioma. Int Ophthalmol Clin. 2010; 50(4):15-25

25. Schwartz SR, Blei F, Ceisler E, Steele M, Furlan L, Kodsi S. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. JAAPOS. 2006;10(3):262-268

26. Chamlin SL, Haggstrom AN, Drolet BA, et al. Multicenter prospective study of ulcerated hemangiomas [published correction appears in J Pediatr. 2008;152(4):597]. J Pediatr. 2007;151 (6):684-689

27. Connelly EA, Viera M, Price C, Waner M. Segmental hemangioma of infancy complicated by life-threatening arterial bleed. Pediatr Dermatol. 2009;26(4):469-472

28. Garzon MC, Epstein LG, Heyer GL, et al. PHACE syndrome: consensus-derived diagnosis and care recommendations. J Pediatr. 2016;178:24-33

29. Hoeger PH, Harper JI, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. The European Journal of Pediatrics. 2015; 174 (7): 855-65.

30. Vleuten C., Schultze Kool L., Verhoeven B., et al. Consensusdocument voor de behandeling van infantiele hemangiomen. 2017 hevas.eu › HEVAS_richtlijnen_2017_WEB.

31. Chinnadurai S, Snyder K, Sathe N, et al. Diagnosis and Management of Infantile Hemangioma. Agency for Healthcare Research and Quality (US); 2016 Jan. Report No.: 16-EHC002-EF.

32. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Tai'eb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651

33. Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138(4):e20160353

34. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128-140

35. Baselga Torres, Bernabéu Wittel, et al. Spanish consensus on infantile haemangioma. An. Pediat.r (Barc). 2016; 85(5): 256-265

36. Bayart C.B., Tamburro J.E., et al. Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study. Pediatr Dermatol. 2017; 34(4): 413-421.

37. Smithson SL, Rademaker M, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Australasian Journal of Dermatology. 2017; 58(2): 155-159.

38. Solman L, Glover M, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. British Journal of Dermatology 2018; 179(3): 582-589

39. Leaute-Labreze C., Hoeger P., Mazereeuw-Hautier J. et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N. Engl. J. Med. 2015; 372:735–46.

40. Wedgeworth E., Glover M., Irvine A.D., et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. British Journal of Dermatology 2016; 174(3): 594-601.

41. Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol. 2011;28(2):169-171

42. Prey S, Voisard JJ, Delarue A, et al. Safety of propranolol therapy for severe infantile hemangioma. JAMA. 2016;315(4):413-415

43. Raphael MF, Breugem CC, Vlasveld FA, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: a cohort study. J Am Acad Dermatol. 2015;72(3):465-472

44. Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016; 137(4):e20151754

45. Chang L., Gu Y., Yu Z., et al. When to stop propranolol for infantile hemangioma. Scientific Reports 2017; 22(7): 43292.

46. Greene AK, Couto RA. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plast Reconstr Surg. 2011;128(3):743-752

47. Chinnadurai S, Fonnesbeck C, Snyder KM, et al. Pharmacologic interventions for infantile hemangioma: a meta-analysis. Pediatrics. 2016;137(2):e20153896

48. Буторина А.В. Лечение сосудистых новообразований у детей: метод, рек. М., 2000. 42с.

49. Bartoshesky L.E. Corticosteroid treatment of cutaneous hemangiomas: how effective a report on 24 children. Clin. Pediatr. 1978; 17: 629-638.

50. Nguyen J.F., Fay A. Pharmacologic therapy for periocular infantile hemangiomas: a review of the literature. Semin. Ophthalmol. 2009; 24(3): 178-184.

51. George M.E., Sharma V., et al Adverse Effects of Systemic Glucocorticosteroid Therapy in Infants With Hemangiomas. Arch. Dermatol. 2004; 140(8): 963-969.

52. Cogen M.S. Eyelid depigmentation following corticosteroid injection for infantile ocular adnexal hemangioma. J. Pediatr. Ophthalmol. Strabismus. 1989; 26 (1): 35-38.

53. Gawrych E. Intralesional corticosteroid therapy in infantile hemangiomas. Ann. Acad. Med. Stetin. 2009; 55(1): 15-21.

54. Pope E. Oral Versus High-Dose Pulse Corticosteroids for Problematic Infantile Hemangiomas: A Randomized, Controlled Trial. Pediatrics. 2007; 119(6): 1239-1247.

55. Gnarra M., Solman L., Harper J.I., Syed S.B. Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. Br J Dermatol. 2015; 173(1): 242-6.

56. Breur J.M., de Graaf M., Breugem C.C., Pasmans S.G. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol. 2011; 28(2): 169–171.

57. Greenberger S., Yuan S., Walsh L.A., et al. Rapamycin suppresses self-renewal and vsculogenic potential of stem cells isolated from infantile hemangioma. J. Invest. Dermatol. 2011; 131(12): 2467–2476.

58. Kaylani S., Theos A.J., Pressey J.G. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr. Dermatol. 2013; 30(6): 194–7.

59. Hutchins K.K., Ross R.D., Kobayashi D. et al. Treatment of Refractory Infantile Hemangiomas and Pulmonary Hypertension With Sirolimus in a Pediatric Patient. Journal of Pediatric Hematology Oncology. 2017; 39(7): 391–393.

60. Puttgen K, Lucky A, Adams D, et al; Hemangioma Investigator Group. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016; 138(3):e20160355

61. Chinnadurai S, Snyder K, Sathe N, et al. Diagnosis and Management of Infantile Hemangioma. Rockville, MD: Agency for Healthcare Research and Quality; 2016

62. Ng M, Knuth C, Weisbrod C, Murthy A. Propranolol therapy for problematic infantile hemangioma. Ann Plast Surg. 2016;76(3):306-310

63. Frommelt P., Juern A., Siegel D., et al. Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma. Pediatric dermatology. 2016; 33(4): 405-414.

64. Puttgen K., Lucky A., Adams D., et al. Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics. 2016; 138(3).

65. https://www.kinderformularium.nl/

66. Chowdri NA, Darzi MA, Fazili Z, Iqbal S. Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. Ann Plast Surg. 1994;33(1):46-51

67. Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases. J Pediatr Surg. 2000; 35(3):420-423

68. Buckmiller LM, Francis CL, Glade RS. Intralesional steroid injection for proliferative parotid hemangiomas. Int J Pediatr Otorhinolaryngol. 2008; 72(1):81-87

69. Prasetyono TO, Djoenaedi I. Efficacy of intralesional steroid injection in head and neck hemangioma: a systematic review. Ann Plast Surg. 2011;66(1):98-106

70. Mulliken JB. Vascular malformation. In: Thorne CH, Beasley RW, Aston SJ, et al. eds. Grabb and Smith’s Plastic Surgery. 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2007:191–200

71. Prasetyono, T. O. H., Djoenaedi, I. Efficacy of Intralesional Steroid Injection in Head and Neck Hemangioma. Annals of Plastic Surgery,2011; 66(1), 98–106.

72. Sloan GM, Reinisch JF, Nichter LS, Saber WL, Lew K, Morwood DT. Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg. 1989;83(3):459-467

73. Chowdri NA, Darzi MA, Fazili Z, Iqbal S. Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. Ann Plast Surg. 1994;33(1):46-51

74. Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases. J Pediatr Surg. 2000; 35(3):420-423

75. Goyal, R., Watts, P., Lane, C. M., Beck, L., Gregory, J. W. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. Ophthalmology, 2004; 111(2), 389–395

76. Egbert JE, Schwartz GS, Walsh AW. Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. Am J Ophthalmol. 1996;121(6): 638-642

77. Egbert JE, Paul S, Engel WK, Summers CG. High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas. Arch Ophthalmol. 2001;119(5):677-683

78. Baselga E, Roe E, Coulie J, et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatol. 2016; 152(11): 1239-1243

79. Boos MD, Castelo-Soccio L. Experience with topical timolol maleate for the treatment of ulcerated infantile hemangiomas (IH). J Am Acad Dermatol. 2016; 74(3):567-570

80. Tay Y.K., Tan S.K. Treatment of infantile hemangiomas with the 595-nm pulsed dye laser using different pulse widths in an Asian population. Lasers Surg Med 2012; 44(2): 93-96.

81. Kessels J.P., Hamers E.T., Ostertag J.U. Superficial hemangioma: pulsed dye laser versus wait- and-see. Dermatol. Surg. 2013; 39(3 Pt 1): 414-421.

82. Civas E., Koc E., Aksoy B., Aksoy H.M. Clinical experience in the treatment of different vascular lesions using a neodymium-doped yttrium aluminum garnet laser. Dermatol Surg 2009; 35(12): 1933-1941.

83. Hartmann F., Lockmann A. Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children. Journal of the European Academy of Dermatology and Venereology. 2017; 31(8): 1372–1379

 

XII. Приложение А1. Состав Рабочей группы

Абушкин И.А., профессор

Гарбузов Р.В., д.м.н.

Голенищев А.И.

Денис А.Г.

Донюш Е.К.

Клецкая И.С.

Купатадзе Д.Д, профессор

Мыльников А.А., к.м.н.

Нарбутов А.Г., к.м.н.

Нурмеев И.Н., профессор

Петрушин А.В., к.м.н.

Поляев Ю.А., профессор

Романов Д.В., к.м.н.

Сафин Д.А.

Хагуров Р.А., к.м.н.

XIII. Приложение А2. Методология разработки клинических рекомендаций

Целевая аудитория данных клинических рекомендаций

Детские хирурги

Педиатры

Онкологи

Дерматологи

Кардиологи

Врачи лучевой диагностики

Порядок обновления клинических рекомендаций

По мере возникновения новых знаний о сути болезни в рекомендации будут внесены соответствующие изменения и дополнения.

XIV. Приложение Б. Алгоритм действия врача

XIV. Приложение В. Информация для пациента